



Oxford Cannabinoid Technologies Holdings Plc
(OCTPL)

Important Notice

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, CANADA, AUSTRALIA OR JAPAN

This presentation and its contents may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part for any purpose without the consent of Oxford Cannabinoid Technologies Holdings Plc. Having taken all reasonable care to ensure that such is the case, the information contained in this presentation is, to the best of the knowledge and belief of the Directors of Oxford Cannabinoid Technologies Holdings Plc, in accordance with the facts and contains no omission likely to affect its import. This presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any securities, or a proposal to make a takeover bid in any jurisdiction. Neither this document nor the fact of its distribution nor the making of the presentation constitutes a recommendation regarding any securities. This presentation is being provided to you for information purposes only.

Certain statements, beliefs and opinions contained in this presentation, particularly those regarding the possible or assumed future financial or other performance of Oxford Cannabinoid Technologies Holdings Plc, industry growth or other trend projections are or may be forward looking statements. Forward-looking statements can be identified by the use of forward looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “plans”, “goal”, “target”, “aim”, “may”, “will”, “would”, “could” or “should” or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future and may be beyond Oxford Cannabinoid Technologies Holdings Plc’s ability to control or predict.

Forward-looking statements are not guarantees of future performance. No representation is made that any of these statements or forecasts will come to pass or that any forecast result will be achieved. The value of investments can go down as well as up and you may not get back your original investment. Past performance is not a guide to future performance.

The distribution of this presentation or any information contained in it may be restricted by law in certain jurisdictions, and any person into whose possession any document containing this presentation or any part of it comes should inform themselves about, and observe, any such restrictions. Any failure to comply with such restrictions may constitute a violation of the laws of any such jurisdiction. By attending the presentation and/or accepting or accessing this document you agree to be bound by the foregoing limitations and conditions and will be taken to have represented, warranted and undertaken that you have read and agree to comply with the contents of this notice.

IF YOU ARE NOT A RELEVANT PERSON OR DO NOT AGREE WITH THE FOREGOING, PLEASE IDENTIFY YOURSELF IMMEDIATELY.

Oxford Cannabinoid Technologies Holdings PLC: Investment Rationale

PHARMACEUTICAL COMPANY DEVELOPING NEXT GENERATION, NON-ADDICTIVE PAIN MEDICATIONS TO REPLACE OPIOIDS

TARGETING THE GLOBAL PAIN MARKET

Estimated to grow to £42.5bn by first launch

FOUR DRUG DEVELOPMENT PROGRAMMES

*IPO proceeds take 2 of these candidates
through phase 1 clinical trials*

STRONG TEAM, BLUE-CHIP SHAREHOLDERS

*Big-pharma experience. FTSE 100 Imperial Brands
representation ensuring high compliance standards*

NEXT GENERATION CANNABINOIDS

*Developing superior, targeted drug products
with market exclusivity*

HIGH POTENTIAL PHARMACEUTICAL BUSINESS MODEL

*Targeting large and orphan indications with approved drug products
physicians can prescribe with confidence*

Note: £42.5bn addressable market by first launch, estimated for 2027; USD/ GBP FX Rate at closing on 31st March 2021 at £1/\$1.3785.



OCTP is a Pharmaceutical Company

OCTP combines innovation with technical expertise to develop a “fast-track” drug development strategy that lowers risk and costs and shortens the time to commercialisation without compromising safety and efficacy



**MED
CANNABIS**

- Limited natural flower and extracts – no improvements to cannabinoid structure permitted
- **Unlicensed products** do not go through robust clinical trials required for licensed medicines
- Lack of proper clinical trial data means they **cannot be approved as a licensed medicine** (FDA/EMA)
- Unlicensed medicines **cannot make claims to treating any disease or condition**
- Unlicensed medicines are, in most instances, **not reimbursable** by insurance companies
- **No market exclusivity**



PHARMA

- OCTP is different. **OCTP IS A PHARMACEUTICAL COMPANY** both in name and in nature
- OCTP invests to **bring drug candidates through robust clinical trials for specific pain indications**
- Process will allow **OCTP to gain regulatory approval** and will **enable doctors to prescribe products**
- **Insurance companies generally cover licensed medicines** making them reimbursable to the patient
- OCTP can improve the structure of cannabinoids creating medicines with **market exclusivity**

Management Team

Team with blue-chip corporate, Big Pharma and biotech experience

Dr. John Lucas: CEO



- 20 years' pharmaceutical and legal experience
- Previously Head of Patents Biosimilars at Boehringer Ingelheim, CEO of Cizzle Biotech and VP Intellectual Property Silence Thera, Metabasis Thera, Transform Pharma and Genset
- MS, Microbiology; PhD, Molecular Genetics; Juris Doctorate (JD), Law
- At OCTP since 2018

Clarissa Sowemimo-Coker: COO and General Counsel



- 13 years' legal experience including 7 years at Penningtons Manches Cooper LLP
- Previously at Three UK and Virgin Media
- Extensive experience delivering management coaching for blue-chip clients including Google
- BA (Hons), Warwick University; BPP Law School
- At OCTP since 2018

Karen Lowe: Financial Director



- Over 20 years in audit and risk management
- Notable roles as Head of Audit at Liverpool City Council and Director of Fraud Risk Management at Mazars LLP
- Risk and Audit Committee at International Personal Finance PLC
- Member of Institute of Risk Management and Accredited Counter Fraud Specialist

Dr. Valentino Parravicini: CSO



- Over 20 years' experience in scientific research
- Over 12 years drug discovery experience in large pharma (GSK; Roche) and biotech
- Team Lead in Translational Science in Biotech
- Project Lead at NIH (US) and NIMR (now Crick Institute; London)
- Doctoral Degree in Medicinal Chemistry
- At OCTP since 2020

Blue Chip and Diverse Board, with FTSE 100 Representation

OCTP has an institutional board with FTSE 100, financial, legal and pharma executives



Neil Mahapatra
Cofounder and Exec
Chairman

- Managing Partner of Kingsley Capital Partners, London based multi family office
- Founding shareholders of OCTP
- Formerly VC/PE at J. Rothschild Capital Management and banking at Morgan Stanley
- BA Biology, Oxford; MBA, Harvard



Julie Pomeroy
NED, Chair Rem.
& Audit Committees

- Over 25 years' experience. CFO and Finance Director roles at Weston Medical, Carter & Carter Plc, Biofutures, and Dillistone Group Plc
- Audit committee, Nottingham University Hospital and Nottinghamshire NHS Trust
- Trained as a Senior Tax Manager at PWC



Dr John Lucas
CEO

- 20 years' pharma and legal experience
- Notably, Head of Patents Biosimilars at Boehringer Ingelheim, CEO of Cizzle Biotech
- Previously VP Intellectual Property at Silence Therapeutics, Metabasis Thera & Genset
- Microbiology; PhD, Molecular Genetics; JD



Bishrut Mukherjee
Non-Executive
Director

- Currently Innovation Manager at Harsco Environmental
- Previously Corporate Development Manager at Imperial Brands Plc and Engineer at BP
- MBA, London Business School, MEng, Imperial College London



Clarissa
Sowemimo-Coker
COO

- 13 years' legal & commercial experience
- Previously at Three UK and Virgin Media
- Extensive experience delivering management coaching for blue-chip clients including Google, McDonald's and Biogen
- BA (Hons), Warwick University; BPP Law



Cheryl Dhillon
Non-Executive
Director

- 29 years' pharmaceutical experience
- Most recently SVP at Otsuka Pharma. Previously EU CFO and Corporate Development Officer at Otsuka.
- Numerous pharma roles at Ares Serono, Elan Corporation and Lorantis Limited






Karen Lowe
Finance Director

- Over 20 years in audit and risk management
- Notable roles as Head of Audit at Liverpool City Council and Director of Fraud Risk Management at Mazars LLP
- Risk and Audit Committee at International Personal Finance PLC

Company is targeting an aggressive share of the global pain market

OCTP will initially target drug development in neuropathic pain, focusing on indications Post Herpetic Neuralgia (PHN) and Irritable Bowel Syndrome (IBS)




Note: £42.5bn Market at forecast drug approval; USD/ GBP FX Rate at closing on 31st March 2021 at £1/\$1.3785; Total Addressable Market ("TAM"); Serviceable Available Market ("SAM"); Serviceable Obtainable Market ("SOM"); Post-herpetic Neuralgia ("PHN"); Irritable Bowel Syndrome ("IBS"). Source: National Institute of General Medical Science; Global Data; Global News Wire; Medgadget; PR News Wire; Bloomberg; CDC; inkwoodresearch; De Gregorio D (2019), WU J (2018), Cremon C. (2017), Yassin M (2018), Pini L.A. (2012), Blake D.R (2006), Abrams D.I (2007), Pinsger M (2006).

OCT is working with research partner Prof. Cader & Oxford StemTech

Stemtech agreement builds on research previously conducted by the Prof. Cader at the University of Oxford

Overview

- **Oxford Cannabinoid Technologies Ltd** signed an exclusive partnership agreement with the **University of Oxford** in 2017
- OCT's pain research at the University of Oxford has been led by **Professor Mohammed (Zameel) Cader** since 2017
- In January 2020 Professor Cader established his own stem cell research organization in **Oxford StemTech**
- Oxford StemTech has **developed a new cell programming method** to reduce the cost and increase the scale of cell programming
- Oxford StemTech is now working with OCT on using its "pain in a dish" translational model



Professor Mohammed (Zameel) Cader




- **Founder:** Oxford StemTech
- **Associate Professor:** University of Oxford
- **Academic Director & Principal Scientist:** IMI StemBANCC
- **Director:** Oxford Headache Centre
- **Strategic Director:** Thames Valley Strategic Clinical Network
- **Neurologist:** John Radcliffe Hospital

Oxford StemTech Agreement

Signed	September 2021
Duration	3 years
Clinical Programmes	OCT drug development programmes 3 and 4
Key Objective	Identify compounds active in translational models of pain and (neuro)inflammation
Technology	Includes induced pluripotent stem cells (iPSC) and microelectrode assays (MEA), which we refer to as "pain in a dish."

Timeline towards first clinical trials in 2022

Significant advancements have been made throughout the life of the company



Note: (1) pCB is a combination of unmodified naturally occurring phytocannabinoids.



Key Highlights and Progress Since IPO



OCT461201
(selective CB2 agonist)

July 2021

- ✓ Signed an agreement with Evotec for preclinical development of OCT461201
- ✓ Company's scale and ability to offer synergistic technologies and services is a key delivery advantage
- ✓ Integrated capabilities spanning all preclinical development activities limits our risk of delay



Inhaled phytocannabinoids

October 2021

- ✓ Use a combination of unnamed pCBs to treat **trigeminal neuralgia**, which produces an “excruciating, stabbing, electric shock-like pain
- ✓ Pulmonary administration aims to limit metabolism and reduce onset time
- ✓ OzUK engaged to formulate cannabinoids provided by Purisys



Cannabinoid derivatives



September 2021

- ✓ Exclusive worldwide license from **Canopy Growth** including 335 cannabinoid derivatives, made and tested, and 14 patent families
- ✓ Library includes derivatives of CBD, THC and CBG
- ✓ Assets significantly advance programmes 3 and 4, plus opportunity for additional programmes
- ✓ Agreement with Dalriada for efficient continuation of drug development
- ✓ Agreement with StemTech for access to state of the art pain model

OCTP's pipeline strategy is robust

Proven pharmaceutical model used for best-practise and to reduce time to value inflection

- **INPUTS:** Diversified inputs to create upside and reduce downside risk
- **SCREENING:** World leading academic and commercial partners
- **DEVELOPMENT:** Pre-clinical testing and randomised controlled trials ("RCTs")
- **MONETISATION:** Multiple opportunities for value creation supplement primary route of drug approval and commercialisation



OCTP has engaged with a number of key partners and CROs

OCTP continues to enhance our partnership model and have engaged with a number of key partners post IPO



Source: Company information.


Pipeline of expanding drug development programmes

Significant value achievable by progressing drug candidates through clinical trials




1. OCT461201: In-licensed compound

- Pre-clinical development underway, initially targeting neuropathic and visceral pain
- Aim to begin Phase 1 in Q3 2022 and Phase 2 in Q2 2023
- Recent patent application filed. If granted will provide 20 years market exclusivity



2. Phytocannabinoids (pCBs): Natural cannabinoid combination

- Pre-clinical development underway, initially targeting trigeminal neuralgia
- Aim to begin Phase 1 in Q3 2022 and Phase 2 in Q2 2023
- Orphan indication market exclusivity 7 yrs US and 10 yrs EU/JP




3. OCTP + Canopy library: Cannabinoid derivative

- Aim to develop up to the pre-clinical stage by Q2 2023
- Diversified pCBs-derivatives
- Expect pursue patent protection and/or orphan market exclusivity (7yr US/10yr EU)



4. OCTP + Canopy Library: Cannabinoid derivative


- Undisclosed Target: New target candidate for pain (and other therapeutic areas)
- Aim to progress to Lead Candidate by Q2 2023
- Initially targeting neuropathic pain market (additional indications include epilepsy and cancer)



OCTP set-out a targeted drug development timeline at IPO

OCTP is investing to bring medically authorised, clinically tested drugs to patients suffering from chronic pain

Indicative Development Timeline



Note: Post-herpetic Neuralgia ("PHN"); Irritable Bowel Syndrome ("IBS").
 Source: Company analysis.

Oxford Cannabinoid Technologies Holdings PLC: Investment Rationale

NON-ADDICTIVE PAIN MEDICATION

**HIGH POTENTIAL PHARMACEUTICAL
BUSINESS MODEL**

DIVERSIFIED PIPELINE

MULTIPLE SHOTS ON GOAL

NEXT GENERATION CANNABINOIDS

BLUE-CHIP SHAREHOLDERS AND PARTNERS

